Tag Archives: Research and Development

Five Keys to Making Biotech Flourish in China

baier-china

As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan. During the keynote lunch of the China Day special program at the 2012 BIO International Convention, David W. Beier, senior vice president at Amgen and former chief domestic policy advisor to Vice President Al Gore, outlined the 5 keys to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

Stock Ticker

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel of experts representing several perspectives on valuation. The session opened with Ben Bonifant, Senior Vice President & Practice Area Leader at Campbell Alliance, presenting results from their Corporate Value Study, which was followed by a discussion examining the key value drivers for emerging companies. Bonifant moderated the panel discussion that featured: Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fireside Chat with Dr. Mikael Dolsten

Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by Mark Schoenebaum, senior biotechnology analyst with ISI Group. Speaking to a full room, Dr. Dolsten touched on Pfizer’s R&D priorities and their increased efforts to focus on investor capital return through a strong mixture of science, business and financial endeavors. In focusing on R&D, Pfizer has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

“Alz” Well That Ends Well: The Beta-Amyloid Debate in Alzheimer’s Research

alzheimers

Researchers and clinicians alike believe there is substantial evidence to support the hypothesis that Alzheimer’s disease (AD) may be caused by deposition of amyloid beta-peptide (Abeta) in plaques in brain tissue. But drugs targeted towards the beta-amyloid have met with significant setbacks challenging whether the target is, in fact, real. With several late stage drugs targeting beta-amyloid poised for market entry, a panel of opinion leaders in the treatment of Alzheimer’s and scientific industry specialists Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Maryland Awards $1 Million to Five Biotech Small Businesses

hands

In effort to spur commercialization and advance treatments for cancer and other diseases, the Maryland Biotechnology Center (MBC) announced earlier this month that it awarded a total of $1 million to five promising life sciences companies through its Biotechnology Commercialization Awards and Translational Research awards. The companies, which received up to $200,000 each, will use the funding to advance cancer therapies, ensure food safety, more quickly detect infectious disease and develop more efficient cardiac repair. Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,